Key result
Structured secondary hypertension protocol identifies causes in ~18% of patients with low cure rates.
Why the study?
It is common practice to use a day-case based approach to identify secondary causes of hypertension, but the diagnostic yield and clinical utility of such protocols remain unclear.
Does a specifically designed secondary hypertension investigation protocol provide sufficient diagnostic yield and clinical utility in hypertensive patients?
Cohort (n=96)
Does a specifically designed secondary hypertension investigation protocol provide sufficient diagnostic yield and clinical utility in hypertensive patients?
A comprehensive day-case protocol for identifying secondary hypertension has a low yield and high cost, questioning the routine justification of such extensive screening.
OBJECTIVE: It has become common practice to use a day-case based approach to identify from the population of hypertensive patients those with an identifiable cause. We aimed to prospectively identify 96 consecutive hypertensive patients undergoing an algorithmic investigation protocol based around two day case hospital attendances. METHODS: The overall diagnostic yield and associated costs were recorded and the patients were observed for a mean of 2.5 years with ambulatory blood pressure (BP) monitoring every three months. RESULTS: A secondary cause of hypertension was identified in 18.1% of patients, three quarters of whom had renovascular disease. There was a fall in blood pressure with time (157/97 vs. 140/85) but this was associated with an increase in the amount of medication required (mean medication score 5.99 vs. 7.65). Improvement in BP occurred irrespective of whether or not a secondary cause was identified. Only 3.2% of patients were cured of their hypertension as a result of enrollment in the protocol. The cost of identifying each case of secondary hypertension was Euro 10, 196. CONCLUSIONS: A comprehensive protocol aimed at identifying secondary hypertension had a low yield, the majority of whom had renovascular disease. In light of recent data illustrating the lack of improvement in BP following dilatation or bypass of atherosclerotic renovascular disease, it is debatable whether searching for it is justifiable.
No takes yet. Share an insight, caveat, or question.
Little et al. (2003) conducted a cohort in Hypertension (n=96). Algorithmic investigation protocol for secondary hypertension was evaluated on Diagnostic yield of secondary hypertension. A specifically designed secondary hypertension investigation protocol identified a secondary cause in 18.1% of patients at a cost of Euro 10,196 per case, with only 3.2% cured of hypertension.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: